Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir-Reference-Cited by-同舟云学术

Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir

Published:2018-04-11 Issue:11 Volume:57 Page:1369-1383
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

German Polina^ORCID,Mathias Anita,Brainard Diana M.,Kearney Brian P.

Funder

Gilead Sciences

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40262-018-0654-5/fulltext.html

Reference73 articles.

1. SOVALDI®, Gilead Sciences Inc. SOVALDI® (sofosbuvir) tablets, for oral use. US Prescribing Information. Foster City, CA. Revised April 2017.

2. SOVALDI®, Gilead Sciences International Ltd. SOVALDI® (sofosbuvir) Tablets, (400 mg sofosbuvir) Antiviral Agent. Product Monograph. Mississauga, Canada. Revised 26 July 2016.

3. SOVALDI®, Gilead Sciences International Ltd. Sovaldi® 400 mg film-coated tablets. Summary of Product Characteristics (SmPC). Cambridge, United Kingdom. Revised March 2017.

4. HARVONI®, Gilead Sciences Inc. HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use. US Prescribing Information. Foster City, CA. Revised April 2017.

5. HARVONI®, Gilead Sciences Inc. HARVONI® (ledipasvir and sofosbuvir) 90 mg/400 mg tablets for oral use. Summary of Product Characteristics (SmPC). Cambridge, United Kingdom. Revised June 2017.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents;Clinical Pharmacokinetics;2023-09-20

2. Development of ledipasvir and sofosbuvir pure certified reference materials for improving quality of pharmaceutical analysis;Journal of Chemical Metrology;2022-12-31

3. Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein;Drug Research;2022-06-20

4. Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice;Pharmaceutics;2022-05-24

5. An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection;Expert Opinion on Pharmacotherapy;2021-07-01